Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in HER2-mutant Stage IV Lung Adenocarcinoma
NCT02979821Phase 2Completed
- Sponsor
- Korean Association for the Study of Targeted Therapy
- Start
- Oct 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poziotinib in lung adenocarcinoma, sponsored by Korean Association for the Study of Targeted Therapy. Primary endpoint: Objective Response Rate at 3 years. Started Oct 2016; status: completed.
02
Drugs
poziotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02979821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979821.